THE CONDITION

Underdiagnosed, Undertreated, and Growing

THE PROOF
20 million men.
Most still undiagnosed.1,2
The TREND
1% decline in
testosterone levels
per year since 19873
THE DATA

Men Today Have Lower Testosterone

A 24-year population study found that American men's testosterone levels have declined approximately 1% per year since 1987, completely independent of aging.3
This is a population-level trend, not an individual failure. Your hypogonadal patients are part of a growing cohort — and most of them don't know it yet.
1%
decline per year since 1987 - independent of aging3
Low Sex Drive
Low Energy
Losing Muscle
Weaker Bones
THE DIAGNOSTIC CHALLENGE

The Symptoms Look Like Everything Else

Low libido, erectile dysfunction, fatigue, weight gain, mood changes - these overlap with stress, aging, depression, and lifestyle factors. Without proactive screening, hypogonadism is easy to miss and easier to attribute to something else.

Recognition of the full spectrum of symptoms, combined with proactive laboratory assessment, improves diagnostic rates regardless of patient age.
Actor Portrayals.
Mood Shifts
Weight Gain
Bad Sleep
Depression
CONFIRMING THE DIAGNOSIS

A Simple Blood Test. That’s the Standard.

Per the KYZATREX Prescribing Information, confirm the diagnosis of hypogonadism prior to initiating KYZATREX by:4
SIMPLE BLOOD TEST
Measure serum testosterone in the morning on two separate days.
BELOW NORMAL RANGE
Both measurements must be confirmed below the normal range before initiating therapy.4
FULL HORMONAL PROFILE
Assess Total T, Free T, and SHBG. High SHBG can suppress Free T even when Total T appears borderline normal.4,5
*Sample values shown for illustration. Reference ranges vary by lab and assay.
⚠︎ KYZATREX is not substitutable with other oral testosterone undecanoate products. Diagnosis must be confirmed before initiating.4
TRT SAFETY - THE EVIDENCE

The Largest Randomized TRT Trial Ever Conducted

The Study
5,246 men. 45–80 years old.
Pre-existing CV risk.6
The FindingS
No difference In prostate cancer
incidence between TRT and placebo groups7 

Actor Portrayals
HR 0.96
Hazard ratio for major cardiovascular events vs. placebo (95% CI: 0.78–1.17)8
5,246
Men enrolled - the largest randomized TRT cardiovascular safety study ever conducted6
No significant
increase in major CV events.8

Ready to Start Treating?

KYZATREX Direct removes the barriers between diagnosis and first dose.

References:

  1. Li Y, Liu M, Cui Y, et al. Increased risk of testosterone deficiency is associated with the systemic immune-inflammation index: a population-based cohort study. Front Endocrinol. 2022;13:975773. doi: 10.3389/fendo.2022.974773
  2. National Population by Characteristics: 2020–2022. Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States: April 1, 2020 to July 1, 2022 (NC-EST2022-SYAEXN). U.S. Census Bureau. https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html. Accessed September 11, 2023.
  3. Travison TG, Araujo AB, O’Donnell AB, et al. A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab. 2007;92(1):196–202.
  4. KYZATREX® [Prescribing Information]. Raleigh, NC: Marius Pharmaceuticals; 2025.
  5. Krakowsky Y, Grober E. Testosterone deficiency — Establishing a biochemical diagnosis. EJIFCC. 2015;26(2):105–113.
  6. Khera M, Rendon DO, Bhattacharya RK, et al. Lessons learned from the TRAVERSE trial. J Sex Med. 2024;16(9):746–748.
  7. Bhasin S, Travison TG, Pencina KM, et al. Prostate safety events during testosterone replacement therapy in men with hypogonadism: a randomized clinical trial. JAMA Netw Open. 2023;6(12):e2348692. doi: 10.1001/jamanetworkopen.2023.48692
  8. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389:107–117. doi: 10.1056/NEJMoa2215025